March 26, 2015

AMENDMENTS AND UPDATES
NRG Oncology has received an Action Letter, updated CAEPR and modified risks for pazobanib, affecting the following studies:

GYNECOLOGIC
GOG-0186J: Amendment 6; version date: 3/9/15.

HEAD AND NECK
RTOG 0912: Study Memo and Amendment 8; version date: 3/11/15. Accrual of new patients must be suspended.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Unsubscribe